Abstract Number: 1695 • ACR Convergence 2022
Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease
Background/Purpose: With an incidence of 10 cases per million and lack of animal or ex vivo disease models, dermatomyositis (DM) remains a debilitating disease without…Abstract Number: 1887 • ACR Convergence 2022
Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box…Abstract Number: 0157 • ACR Convergence 2022
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale
Background/Purpose: Brepocitinib is a novel, orally available, TYK2/JAK1 inhibitor in Phase 3 development for the treatment of dermatomyositis (DM), a chronic immune-mediated disease of the…Abstract Number: 0652 • ACR Convergence 2022
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…Abstract Number: 1696 • ACR Convergence 2022
Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus
Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM…Abstract Number: 2239 • ACR Convergence 2022
Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…Abstract Number: 0159 • ACR Convergence 2022
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
Background/Purpose: Recent observations suggest the importance of the BAFF pathway in the pathogenesis of Idiopathic Inflammatory Myositis (IIM). Elevated serum levels of circulating BAFF in…Abstract Number: 0717 • ACR Convergence 2022
Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States
Background/Purpose: Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by skin manifestations and/or progressive muscle weakness and other systemic manifestations. Patients with DM were…Abstract Number: 1838 • ACR Convergence 2022
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease characterized by muscle weakness, skin rashes, and elevated risk of associated conditions such as interstitial…Abstract Number: 2240 • ACR Convergence 2022
Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody-associated DM sometimes…Abstract Number: 0161 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…Abstract Number: 0824 • ACR Convergence 2022
Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis
Background/Purpose: To describe selected epidemiologic, demographic and outcome data in a cohort of Afro-Caribbean patients diagnosed clinically with dermatomyositis. To demonstrate clinical features of the…Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…Abstract Number: 2241 • ACR Convergence 2022
Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) may harbor autoantibodies that are associated with well-defined clinical phenotypes. The association of these autoantibodies with level of…Abstract Number: 0163 • ACR Convergence 2022
Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic
Background/Purpose: Prior research has shown that viruses may trigger JDM, although the degree to which COVID-19 may serve as a trigger for JDM remains unknown.…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 24
- Next Page »